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Craniopharyngioma are rare histologically benign brain tumors that develop in the pituitary–
hypothalamic area.They may invade nearby anatomical structures causing signiﬁcant rates
of neurological, neurocognitive, and endocrinological complications including remarkable
hypothalamic damage. Information regarding long term implications of the tumors and
treatment in the pediatric population is accumulating, and treatment goals appear to be
changing accordingly. In this review we aim to present data regarding long term compli-
cations of craniopharyngioma in children and adolescents and our experience from a large
tertiary center. Hypothalamic dysfunction was noted to be the most signiﬁcant complica-
tion, adversely affecting quality of life in survivors. Obesity, fatigue, and sleep disorders
are the most notable manifestations of this dysfunction, and treatment is extremely dif-
ﬁcult. Changes in management in recent years show a potential for improved long term
outcomes; we found a trend toward less aggressive surgical management and increasing
use of adjuvant treatment, accompanied by a decrease in complication rates.
Keywords: child, craniopharyngioma, complications, hypothalamic obesity, sleep, pituitary, neurocognitive, recur-
rence
INTRODUCTION
Craniopharyngioma (Cp) tumors are rare epithelial brain tumors
that develop fromremnants of Rathke’s pouch.They canbe located
along an axis extending from the sella turcica, through the pitu-
itary stalk, to the hypothalamus. Tumors are partly cystic and have
benign histological appearance (Bunin et al., 1998; Muller, 2010).
As craniopharyngiomas enlarge they invade nearby anatomical
structures and despite their histology can have an aggressive clini-
cal course. Both the tumor and its treatment can lead to signiﬁcant
neurological and endocrinological complications; themost devas-
tating being related to hypothalamic dysfunction (Sughrue et al.,
2011). Long term survival is high (Poretti et al., 2004); however
complications have serious implications on quality of life. These
tumors present a great challenge to the neurosurgeon due to their
location andproximity to vital structures, and controversy as to the
preferable method for treatment exists. In the past decade treat-
ment goals appear to be changing, with many centers adopting
a less aggressive approach. Advancements in radiation technol-
ogy as well as in chemotherapy methods and medications have
been remarkable and these provide a variety of potential adju-
vant treatments. In this report we aim to review the long term
complications of Cp tumors and their treatment in the pediatric
population; including data from the literature as well as our own
experience.
CRANIOPHARYNGIOMA TREATMENT
The preferable approach for treatment of Cp tumors in children
remains controversial despite many years of experience. In the
past, gross total resection (GTR) of the tumor was the method
of choice (Hoffman et al., 1992; De Vile et al., 1996; Van Effen-
terre and Boch, 2002; Poretti et al., 2004; Caldarelli et al., 2005)
and it remains so in some centers (Caldarelli et al., 2005; Elliott
and Wisoff, 2010). Based on the benign histology of the tumor
this approach is aimed at achieving cure. However, these patients
were found to have a considerable rate of recurrences, occur-
ring in up to one-third of patients (Hoffman et al., 1992; Jung
et al., 2010; Steno et al., 2011) as well as a high rate of compli-
cations and morbidity (Crom et al., 2010; Sughrue et al., 2011).
Hypopituitarism, hypothalamic dysfunction, and neurocognitive
impairments in areas of memory, learning, and school perfor-
mance, are prevalent in series using primarily GTR (Hoffman
et al., 1992; De Vile et al., 1996; Poretti et al., 2004). Taking into
consideration the great signiﬁcance of these morbidities, in recent
years a surgical approach that is more patient and tumor speciﬁc
is gaining acceptance; reserving extensive resections for favorably
located tumors, not involving the hypothalamus (De Vile et al.,
1996; Poretti et al., 2004; Steno et al., 2011). Endoscopic trans-
sphenoidal surgery is used for smaller, primary intrasellar tumors
(Elliott et al., 2011). Characteristically Cp tumors have single or
multiple cysts within the tumor (Steinbok and Hukin, 2010) and
limited resection or cyst decompression is an alternative surgical
approach that addresses Cp more as a chronic disease. In cases of
emergent decompression, this proceduremay allow time for better
planning of future treatment, and a catheter implanted in the cyst
can be used later for administering intra-cystic treatment. In our
experience, even with decompression as a sole treatment, patients
can have a stable course not requiring additional treatment for
prolonged periods.
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Adjuvant treatment: In patients with predominantly cystic
tumors, installation of medications, or radioisotopes to shrink
the tumor may be of beneﬁt (Hukin et al., 2007; Cavalheiro et al.,
2010; Steinbok and Hukin, 2010). Intra-cystic bleomycin (ICB)
for pediatric Cp has been in use in Canada since 1995 (Hukin
et al., 2007), although side effects such as local leakage into adja-
cent brain tissue have raised some concerns and warrants close
monitoring (Lafay-Cousin et al., 2007). Intra-cystic interferon-α
for treatment of patients with Cp has shown good results, with
a reduced complication rate and minimal side effects (Cavalheiro
et al., 2010; Steinbok and Hukin, 2010). Radiation therapy for
pediatric Cp has been in use for more than half a century (Kiehna
andMerchant, 2010); it can be used both as an adjuvant in primary
treatment and for disease recurrence. Limited surgery followed by
radiation might induce favorable outcomes when compared to
more aggressive solely surgical treatments (De Vile et al., 1996;
Merchant et al., 2002; Kiehna and Merchant, 2010). Radiotherapy
might have signiﬁcant short and long term adverse effects and
these pose a major limitation to the use of this treatment modality
in children (Merchant et al., 2002; Caldarelli et al., 2005; Kiehna
and Merchant, 2010).
Determining the exact prevalence of outcomes for the differ-
ent treatment modalities is complicated by multiple factors and
no randomized control trials exist in the pediatric population.
Decisions regarding surgery and adjuvant therapy are done based
on tumor and child characteristics as well as the treating team’s
approach and experience. Late outcomes are also inﬂuenced by
treatments given for disease recurrence. In addition, outcomes are
not uniformly assessed or presented. Despite these limitations,
there are data from the literature suggesting improved outcomes
for less aggressive surgical approaches combined with radiation
in terms of disease recurrence, neurocognitive functioning, and
prevalence of diabetes insipidus (DI) and severe obesity. These are
presented in more detail in the following sections.
Over the past decade, the surgical approach to Cp in our insti-
tution has changed to become less aggressive (Figure 1). In the
years 1975–1989 90% of children had a total resection (Hoffman
et al., 1992), between 1990 and 2001 86% (Ahmet et al., 2006)
had a total resection and from 2001 to 2011 only 10% had a total
resection. In recent years radiation and intra-cystic chemotherapy
are given to a larger percent of patients.
TUMOR RECURRENCE AND REGROWTH
Recurrence and regrowth in Cp are not uncommon and can be
expected even with extensive resection. Tumor recurrences are
often asymptomatic and diagnosed on routine follow-up imaging
(Hoffman et al., 1992; Elliott and Wisoff, 2010). Rates of recur-
rence following GTR range between 17 and 36% (Hoffman et al.,
1992; Merchant et al., 2002; Poretti et al., 2004; Ahmet et al., 2006;
Elliott andWisoff, 2010; Jung et al., 2010; Elliott et al., 2011; Steno
et al., 2011); however some report much lower rates of 7.7–10%
following neuroradiologically conﬁrmed total resection by trans-
cranial approach (De Vile et al., 1996; Caldarelli et al., 2005), or
with trans-sphenoidal GTR (Elliott et al., 2011). Regrowth rates
after incomplete removal are higher, ranging between 43 and 67%
(Jung et al., 2010; Steno et al., 2011). The 10-year recurrence rate
after combined surgical and radiation treatment is reported to be
FIGURE 1 |Trends in the surgical approach to craniopharyngioma
1975–2011. Prevalence of gross total resection (GTR – blue), subtotal
resection (STR – red), and cyst decompression (Decompression – green)
surgery as the primary treatment for pediatric craniopharyngioma in our
institution over more than three decades; 1975–1989 (Hoffman et al., 1992),
1990–2001 (Ahmet et al., 2006), 2001–2011.
lower, ranging between 0 and 30%, with some reports demon-
strating improved disease control for a combination of biopsy
or cyst resection and radiation compared with subtotal resection
and radiation (Clayton et al., 1988; Stripp et al., 2004; Lin et al.,
2008; Kiehna and Merchant, 2010). Recurrences occur at variable
time intervals from the initial surgery, including many years after
surgery (Hoffman et al., 1992; De Vile et al., 1996; Merchant et al.,
2002;Caldarelli et al., 2005; Elliott andWisoff, 2010) and occasion-
ally appear in a location away from the original Cp site (Caldarelli
et al., 2005). Mean interval from treatment to recurrence is most
commonly reported to be approximately 3 years (Hoffman et al.,
1992; Poretti et al., 2004; Caldarelli et al., 2005; Elliott andWisoff,
2010). Risk factors for recurrence include a large tumor size, young
age, and severe hydrocephalus at presentation; incomplete tumor
resection andprevious recurrence are additional risk factors (Hoff-
man et al., 1992;DeVile et al., 1996;Van Effenterre andBoch, 2002;
Poretti et al., 2004; Caldarelli et al., 2005; Elliott andWisoff, 2010;
Jane et al., 2010; Jung et al., 2010; Steno et al., 2011).
PITUITARY DEFICIENCIES
Pituitary hormone deﬁciencies are common in children treated
for Cp. At diagnosis 40–87% of patients (Hoffman et al., 1992;
Caldarelli et al., 2005; Muller, 2008) have been identiﬁed to have
at least one hormone deﬁciency and 17–27% (Hoffman et al.,
1992; Muller, 2008; Elliott and Wisoff, 2010) have been reported
to have DI. Post surgery, the rate of pituitary hormone deﬁcien-
cies increases and has been reported to be 80–100% (Hoffman
et al., 1992; De Vile et al., 1996; Merchant et al., 2002; Muller
et al., 2004; Poretti et al., 2004; Caldarelli et al., 2005; Elliott and
Wisoff, 2010; Jung et al., 2010; Steno et al., 2011). Prevalence is
comparable even with pituitary stalk preservation (Jung et al.,
2010). We have found rates similar to those reported in the lit-
erature for individual deﬁciencies and an encouraging decrease
in rates of panhypopituitarism with less aggressive treatment
(Figure 2). A majority of patients need both anterior and pos-
terior pituitary hormonal replacement. The evaluation of anterior
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FIGURE 2 | Prevalence of complications following Cp treatment in the
past two decades. Prevalence of hypopituitarism (Hypopit), diabetes
insipidus (DI), and obesity between the years 1990–2001 (Ahmet et al.,
2006; blue) and 2001–2011 (red). Obesity (Ob) deﬁned as BMI>95th
percentile for age and gender. Severe obesity deﬁned as BMI>99th
percentile for age and gender or BMI>40 kg/m2 if more than 18 years old);
Severe Ob/Ob – the percent of obese patients with severe obesity.
pituitary hormone deﬁciencies is not uniform in reports from
different studies. Those based on rates of hormone replacement
might underestimate the prevalence of growth hormone (GH)
and gonadotropin deﬁciencies or overestimate ACTH deﬁciency if
reporting hormone replacement at any time point. Overall,ACTH
deﬁciency is described to range between 70 and 95%, with no
clear trend related to treatment modality. TSH deﬁciency ranges
between 80 and 96% in different series with a slightly higher rate
for the combination of surgery and radiation compared to more
aggressive surgery. Gonadotropin deﬁciency is most commonly
described to be around 30–40%. Clinical or biochemical GH deﬁ-
ciency has been described at diagnosis in 26–75% of children with
Cp (Ahmet et al., 2006; Muller, 2008), and decreases in height SD
score (SDS) may occur years before diagnosis (Muller et al., 2004).
GH deﬁciency following treatment for Cp is common, found in
about 70–92% of patients, the literature does not clearly delineate
a signiﬁcant difference between the treatment modalities (Muller
et al., 2004, 2011; Halac and Zimmerman, 2005; Crom et al., 2010)
and a good response to GH treatment is described (Geffner et al.,
2004).
Transient post-surgical DI is a prevalent ﬁnding that has been
described to occur in almost all patients in some series (Poretti
et al., 2004; Caldarelli et al., 2005). In our experience, the rapid
shifts in serum sodium that commonly complicated the course
post GTR and signiﬁcantly prolonged the post-surgical admission
have decreased remarkably in magnitude when using less aggres-
sive surgical procedures. We also noted a decrease in prevalence
of permanent DI (Figure 2). Permanent DI after treatment was
found in different series to range between 60–90% after aggres-
sive surgery and 50–55% after less aggressive surgery combined
with radiation therapy (Hoffman et al., 1992; De Vile et al., 1996;
Merchant et al., 2002; Poretti et al., 2004; Caldarelli et al., 2005;
Ahmet et al., 2006; Elliott and Wisoff, 2010; Elliott et al., 2011;
Muller et al.,2011).Replacement treatment for pituitaryhormones
is in most instances readily accessible; however hypothalamic
injury in this population might interfere with thirst regulation
complicating the DI management and putting the children at risk
for life threatening electrolyte imbalances. Pituitary hormone deﬁ-
ciencies might also occur late, particularly when adjuvant treat-
ment is used, therefore monitoring pituitary function is a life-long
requirement.
LINEAR GROWTH
Despite the common occurrence of GH deﬁciency after treatment
for Cp not all require GH replacement for growth induction. In
a study of Cp-related hypothalamic obesity (CRHO) conducted
by our group, one-third of the patients were growing despite
GH deﬁciency and no supplementation (O’gorman et al., 2010b;
Simoneau-Roy et al., 2010); another study found an even higher
rate of normal growth without GH (Srinivasan et al., 2004).
Patients with hypothalamic involvement were found to achieve
normal height at last follow-up more often than patients without
hypothalamic involvement (Muller et al., 2004). This phenomenon
of “growth without GH”has been described in Cp patients almost
ﬁve decades ago (Matson, 1964). The physiology of growth in
these cases is not fully understood. Insulin and leptin are thought
to induce growth in the fetus and in obese children and are hypoth-
esized to induce growth in Cp (Costin et al., 1976; Geffner, 1996;
Phillip et al., 2002). Leptin was shown to have characteristics of
a bone growth factor acting directly at the level of bone growth
centers, independently of GH (Phillip et al., 2002). Mechanisms
by which insulin stimulates growth include its known anabolic
effects; at high levels it may bind to the insulin-like growth factor-
1 (IGF-1) receptor and induce growth, and through its actions to
decrease IGF-binding protein 1 levels it may increase levels of free
IGF-1 (Phillip et al., 2002). In support of this theory, obese Cp
patients were found to have a higher height SDS at diagnosis and
at last follow-up with no difference in the usage of GH, thyroxine,
or hydrocortisone (Muller et al., 2001); and increased insulin levels
were found in children with Cp. In contrast, another study found
that children who were growing despite GH deﬁciency were not
different from those requiring GH treatment in terms of anthro-
pometrical measures, body composition, and metabolic indexes;
including insulin levels (Srinivasan et al., 2004). Sexhormonesmay
also induce growth in these patients (Phillip et al., 2002). Finally,
the effects of other local growth factors acting on bone have been
hypothesized to contribute to this phenomenon (Geffner, 1996;
Phillip et al., 2002).
HYPOTHALAMIC DYSFUNCTION
Hypothalamic dysfunction in children with Cp is common and
has been found at diagnosis in 35% of patients (Elliott andWisoff,
2010). It dramatically increases following treatment; in some series
occurring in up to 65–80% of patients (Poretti et al., 2004; Elliott
and Wisoff, 2010). This complication can signiﬁcantly compro-
mise health-related quality of life (HRQoL) and be extremely
resilient to treatment. Some of the manifestations such as obesity
can be quantiﬁed by relatively simple anthropometric measures;
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however, othersmay bemore elusive in nature. Fatigue, behavioral
changes, circadian rhythm, and sleep irregularities and imbalances
in regulation thirst, body temperature, heart rate, or blood pres-
sure might be more difﬁcult for both patients and physicians
to appreciate. These dysfunctions are inter-related in a way that
can worsen outcome. The pre-surgical evaluation of hypothala-
mic damage might be difﬁcult both clinically and radiologically
(Steno et al., 2011); tumor involvement of the third ventricle, or
obstructive hydrocephalus are suggestive ﬁndings (Caldarelli et al.,
2005).
SLEEP DYSREGULATION
Hypothalamic injury may result in disturbances in sleep–wake
patterns. Our and others’ clinical experience is that patients with
CRHO commonly suffer from an altered pattern of circadian
rhythm with early morning awakening, followed by an extra
period of sleep during the afternoon. Thus, sleep fragmentation
and increased daytime sleepiness are common. Increased day-
time sleepiness has been reported by one-third of children with
Cp that were surveyed with a prevalence of 40% in the severely
obese children (Muller et al., 2002, 2006b; Snow et al., 2002;
Poretti et al., 2004). Actigraph recording in three patients with
Cp and daytime hypersomnolence demonstrated irregular bed-
times, frequent night-time activity, and inappropriate daytime
episodes of rest, consistent with our clinical experience (Lip-
ton et al., 2009). Melatonin secretion occurs during hours of
darkness; it affects sleep patterns and potentially has a role in
circadian rhythm regulation. An altered pattern of diurnal mela-
tonin secretion with decreased night-time melatonin levels was
detected in severely obese Cp patients (Muller et al., 2002; Lip-
ton et al., 2009). Nocturnal levels had a negative relation to both
the degree of obesity and the sleepiness scoring. Melatonin treat-
ment in Cp patients with severe daytime sleepiness resulted in
an increment in morning and night melatonin levels, improve-
ment in daytime sleepiness and physical activity (Muller et al.,
2006b).
Modaﬁnil is a wake-promoting agent that has shown beneﬁ-
cial effects in adults with Cp-related hypersomnolence (Crowley
et al., 2011). We have offered this medication to two patients with
hypothalamic obesity (HO) and signiﬁcant daytime fatigue related
to treatment for tumors in the hypothalamic area. Both patients
reported a remarkable improvement in alertness and activity tol-
erance, and themedication was well tolerated; no signiﬁcant effect
on weight has been noticed. Future research on the effects of this
medication in children with Cp is warranted.
In addition to the effect of hypothalamic damage, the obe-
sity and metabolic dysfunction in patients with Cp might be
associated with sleep-disordered breathing (Redline et al., 2007).
Our group found sleep-disordered breathing to be increased
in adolescents with Cp-related obesity compared with BMI-
matched controls (O’gorman et al., 2010b). Speciﬁcally, increased
sleep fragmentation and reduced sleep efﬁciency were found
in children with Cp; the obstructive apnea–hypopnea index
was higher and correlated negatively with adiponectin levels,
an adipokine with insulin sensitizing properties. We propose
considering routine polysomnography in obese patients with
craniopharyngioma.
ACTIVITY AND ENERGY EXPENDITURE
Weight gain in patients with Cp was traditionally thought to be
induced by hyperphagia; however a number of studies suggest that
although subjective hunger may be higher, energy intake is not
increased when compared to control subjects (Harz et al., 2003;
Holmer et al., 2010). A decreased metabolic rate (both resting
and total energy expenditure) has been suggested to contribute
to weight gain in this population. Adults with childhood onset
Cp as well as children with Cp were found to have a lower rest-
ing energy expenditure (REE) compared to controls (Shaikh et al.,
2008b; Holmer et al., 2010; Kim et al., 2010). This difference was
not explained by differences in body composition. The energy
intake/REE ratio was signiﬁcantly lower in those with tumors
involving the third ventricle (Holmer et al., 2010). Patients with
childhood Cp were also found to have decreased physical activity
compared to healthy obese and normal weight controls contribut-
ing to overall lowering of total energy expenditure (Harz et al.,
2003; Shaikh et al., 2008b; Holmer et al., 2009, 2010). Factors that
could potentially contribute to decreased activity are neurologi-
cal and visual deﬁcits, increased daytime sleepiness, low levels of
testosterone and GH and psychosocial difﬁculties such as teas-
ing and bullying leading to self-consciousness about engaging in
physical activity.
WEIGHT GAIN AND OBESITY
Of themanifestations of hypothalamic damage in children treated
for Cp, rapid weight gain is the most concerning complication
for patients, their families, and practitioners. This occurs despite
adequate replacement of pituitary hormone deﬁciencies. The
hypothalamic disturbance in energy management contributes to
obesity and is further augmented by factors limiting activity. There
is evidence demonstrating increased weight gain in children with
Cp occurring years before diagnosis (Muller et al., 2004). At diag-
nosis 12–19% of patients were reported to be obese (Hoffman
et al., 1992; Poretti et al., 2004; Ahmet et al., 2006; Muller, 2008).
Obesity develops early after treatment and weight gain was found
to rapidly increase in the ﬁrst 6–12months after treatment (Muller
et al., 2001; Ahmet et al., 2006); later on BMI stabilizes but obe-
sity continues to remain a problem (Ahmet et al., 2006; Holmer
et al., 2010). Following treatment, the prevalence of obesity is
higher, reaching up to 55% (Hoffman et al., 1992; Muller et al.,
2001, 2003b; Poretti et al., 2004; Srinivasan et al., 2004; Ahmet
et al., 2006; Lek et al., 2010; O’gorman et al., 2010b; Elliott et al.,
2011). Reviewof our patients indicates a lower prevalence of severe
obesity associated with less aggressive surgery (Figure 2). This is
supported by more recent reports of lower rates of severe obe-
sity after combined surgical and radiation approaches (Lin et al.,
2008; Crom et al., 2010). However the literature does not demon-
strate a signiﬁcant change in the prevalence of overall obesity with
the change in treatment approach. This might be related to the
small number of patients in studies as well as to the approach to
assessment of obesity; more detailed stratiﬁcation of the degree of
obesity appears to provide additional information. When evalu-
ating body composition and fat distribution in children with Cp,
results are conﬂicting; some studies have demonstrated patients
to have increased fat free mass and muscle mass when compared
to controls (Holmer et al., 2010; Kim et al., 2010) while others
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found comparable fatmass inCp patients and controls (Srinivasan
et al., 2004; Shaikh et al., 2008a). Excess weight has a signiﬁcantly
adverse effect on HRQoL and self-esteem (Hoffman et al., 1992;
Muller et al., 2001) and is associated with difﬁculties at school as
well as at home. Adults with childhood onset Cp and obesity also
reported a higher tendency to restrict food intake for controlling
body weight compared with controls (Holmer et al., 2010). Risk
factors for HO include hypothalamic involvement of the tumor
or treatment, tumor growth inside the cavity of the third ven-
tricle, pre-operative hydrocephalus, large tumor size, a lower rate
of successful GTR, higher radiation doses to the hypothalamus
(>51Gy), higher BMI in early childhood, higher BMI, and height
SDS at diagnosis and familial predisposition for obesity (Muller
et al., 2001, 2003b, 2004, 2011; Lustig, 2002; Lustig et al., 2003b;
Caldarelli et al., 2005; Ahmet et al., 2006; Holmer et al., 2009, 2010;
Lek et al., 2010; Roth et al., 2011; Steno et al., 2011). The dose and
duration of post-operative dexamethasone treatment was found
to have only a short term effect on weight gain and treatment cor-
related with weight gain during the ﬁrst post-operative year but
not with long term development of obesity (Muller et al., 2003b).
METABOLIC SYNDROME
In a study conducted by our group, children and adolescents with
CRHO were found to have an increased rate of the metabolic syn-
drome (MS) occurring in 10 out of 15 subjects studied (66%)
compared to 3 out of 15 BMI-matched controls (20%; Simoneau-
Roy et al., 2010). Impaired glucose tolerance wasmore prevalent in
the Cp subjects; they also demonstrated higher levels of free fatty
acids and TNF-alpha, molecules associated with MS (Figure 3).
In agreement with our results, children and adolescents follow-
ing Cp removal were found to have features of the MS, including
higher abdominal fat and less favorable lipid proﬁles when com-
pared with matched controls (Srinivasan et al., 2004). In contrast,
adults with childhood onset Cp, were demonstrated increased risk
for cardiovascular disease compared to a control group; however,
after adjustment for BMI, these differences disappeared (Holmer
et al., 2009). Furtherwork is needed to assess longer termoutcomes
related to risk for type 2 diabetes and cardiovascular disease in this
population.
FIGURE 3 | Features of the metabolic syndrome in patients with
craniopharyngioma and control subjects.
AUTONOMOUS NERVOUS SYSTEM BALANCE IN
CRANIOPHARYNGIOMA
The hypothalamic regulation of appetite and energy homeostasis
is a complex system involving hormonal and neuronal pathways
connecting the hypothalamus with the alimentary system and
periphery, including adipose tissue which also produces hormones
and cytokines. The hypothalamus receives input regarding adipose
accumulation, satiety, and metabolism from peripheral hormones
including leptin, ghrelin, and insulin respectively (Lustig, 2002); it
exerts its efferent signal via the autonomic nervous system (ANS).
Damage that lowers the sympathetic nervous system (SNS) activ-
ity and/or increases the parasympathetic nervous system (PNS)
activity could contribute to a positive energy balance and weight
gain and both conditions have been theorized to contribute to the
development of HO(Lustig,2002;Hochberg andHochberg,2010).
The common symptomof increased fatigue in these patients could
also be related to a decreased sympathetic tone.
In support of decreased activity of the SNS, urine cate-
cholamine levels were found to be lower in children with Cp
compared to controls (Coutant et al., 2003) and levels negatively
associate with the degree of obesity and physical activity (Roth
et al., 2007). Further support comes from the improvement seen in
terms of weight, activity, and attention when treating Cp patients
with medications that increase sympathetic tone (Mason et al.,
2002; Ismail et al., 2006; Danielsson et al., 2007; Schultes et al.,
2009). SNSactivity is thought todecrease insulin secretion through
inhibition of pancreatic beta-cells and to inhibit insulin stimu-
lated leptin release from adipocytes (Cammisotto and Bukowiecki,
2002; Lustig, 2003). Elevated levels of both hormones have been
reported in Cp-related obesity, even after adjusting for fat mass,
andmay in part be due to an decreased sympathetic activity (Gold-
stone et al., 2005; Shaikh et al., 2008a; Guran et al., 2009; Holmer
et al., 2009, 2010; O’gorman et al., 2010a; Simoneau-Roy et al.,
2010; Roth et al., 2011).
Increased vagal activity as a result of hypothalamic damagemay
lead to increased pancreatic beta-cell stimulation and hypersecre-
tion of insulin (Lustig, 2002). This is supported by the aforemen-
tioned increased insulin levels in patients with Cp-related obesity
and by improvement in terms of weight gain with treatments tar-
geted at suppressing beta-cell activity. Octreotide has been found
to attenuate glucose induced insulin excursions; and to result in
reduced weight gain, or in some cases, weight loss (Lustig et al.,
1999, 2003a; Inge et al., 2007). Our group has investigated the
combined effect of two medications on children with Cp and HO;
diazoxide in order to decrease insulin secretion and metformin to
enhance insulin action. A decrease in weight gain and BMI was
also noted and the best response was seen in subjects with the
highest glucose stimulated insulin secretion prior to receiving the
medication (Hamilton et al., 2011).
NEUROLOGICAL AND VISUAL OUTCOMES
Due to the tumor’s location, visual deﬁcits in children with Cp are
relatively common including impairments in both visual acuity
and visual ﬁelds. Visual impairment was found to exist as an ini-
tial manifestation of pediatric Cp inmore than half of the patients
(Muller, 2008) with some improvement in vision in 41–48% of
patients post-surgically (Caldarelli et al., 2005; Elliott et al., 2011).
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Risk factors for post-surgical visual impairment include severe
pre-surgical visual deﬁcits and tumors located in the prechias-
matic area (Caldarelli et al., 2005; Steno et al., 2011). Despite
potential visual improvement after treatment overall post treat-
ment rates of visual impairment are reported in about 45–70%
of patients; different treatment modalities result in comparable
rates (DeVile et al., 1996; Stripp et al., 2004; Merchant et al., 2006;
Lin et al., 2008; Crom et al., 2010). Improved results were found
in patients that underwent a trans-sphenoidal procedure (Elliott
et al., 2011).
Neurological abnormalities include hemiparesis, epilepsy, cra-
nial nerve deﬁcits, learning problems,hearing loss, cerebrovascular
disease manifestations, and headaches (Merchant et al., 2002;
Crom et al., 2010; Elliott and Wisoff, 2010). A signiﬁcant part
of these are transient and the total prevalence of long term neuro-
logical complications is reported to be 8% (Caldarelli et al., 2005),
however rises to 36% for giant tumors (Elliott and Wisoff, 2010)
and 30% when including visual and neurological complications
together (Poretti et al., 2004).
HEALTH-RELATED QUALITY OF LIFE, PSYCHOSOCIAL
FUNCTIONING AND NEUROCOGNITIVE OUTCOME
Health-related quality of life in children can be affected by both
the Cp tumor itself and the treatment received. Reports assess-
ing psychosocial and physical functioning, show variable results
ranging from excellent in a majority of subjects to impaired
function in almost half of the patients (Hoffman et al., 1992;
Van Effenterre and Boch, 2002; Poretti et al., 2004). The most
common areas of difﬁculty reported include social and emo-
tional functioning, with patients rating their psychosocial health
to be lower than their physical health (Poretti et al., 2004). Other
challenges included somatic complaints such as pain, mobility,
and self-care (Merchant et al., 2002; Poretti et al., 2004). Chil-
dren with Cp were found to have lower HRQoL in all domains;
and parental reports of children’s social and total function-
ing were signiﬁcantly lower compared to scores from parents
of survivors of other cancers (Rakhshani et al., 2010). Behav-
ioral questionnaires indicate more frequent presence of psy-
chopathological symptoms, including depression, anxiety, and
withdrawal. The most frequent problems in children’s every-
day functioning included inability to control emotions, difﬁcul-
ties in learning, unsatisfactory peer relationships, and concerns
regarding physical appearance (Crom et al., 2010; Ondruch et al.,
2011).
Factors associated with worse outcomes in terms of HRQoL
as well as psychosocial and neurocognitive functioning include
younger age at diagnosis and pre-operative functional impair-
ment; tumor characteristics including larger size, hypothalamic,
and third ventricle involvement at presentation. Treatment type
has also been implicated, with worse outcomes for surgery alone
compared to limited surgery and radiotherapy and for multiple
operations for tumor recurrence (Merchant et al., 2002; Poretti
et al., 2004). Neurological, ophthalmological, and endocrine
sequelae adversely affect outcome (Hoffman et al., 1992;Merchant
et al., 2002; Van Effenterre and Boch, 2002; Muller et al., 2003a;
Poretti et al., 2004; Elliott and Wisoff, 2010; Steno et al., 2011)
and hypothalamic dysfunction was found to have an important
negative effect on physical ability, social functioning, and body
image (Muller et al., 2001, 2003a; Poretti et al., 2004).
In addition to psychosocial function, long term neurocognitive
complications following treatment for Cp may include cogni-
tive problems, particularly affecting attention, executive function,
working memory, and episodic memory (Cavazzuti et al., 1983;
Riva et al., 1998; Carpentieri et al., 2001; Poretti et al., 2004; Sands
et al., 2005; Kiehna et al., 2006; Crom et al., 2010; Ondruch et al.,
2011). Various neurocognitive outcomes were assessed in differ-
ent studies making comparison difﬁcult. Series including children
treated primarily with GTR report 57% of patients exhibit post
treatment memory deﬁcits (Hoffman et al., 1992; Poretti et al.,
2004). A signiﬁcant number of long term survivors of pediatric
Cp treated primarily with radiation and subtotal surgical resec-
tion, were found to have psychological and educational deﬁcits
(Crom et al., 2010). Neurocognitive deﬁcits have ranged to include
memory disturbances, slower cognitive speed, attention problems,
and behavioral lability (Cavazzuti et al., 1983; Colangelo et al.,
1990; Carpentieri et al., 2001; Kiehna et al., 2006; Crom et al.,
2010; Ondruch et al., 2011). While intact intellectual function-
ing has been reported in up to 82% of patients, visual memory is
reduced, despite normal visual–spatial abilities (Crom et al., 2010;
Ondruch et al., 2011). The acquired deﬁcits in higher cognitive
processing such as attention problems are considered precursors
to poor academic achievement and vocational failure. Follow-
ing radiation therapy IQ was found to remain stable overall,
with improved results for older children (Kiehna and Merchant,
2010). The impact of conformal radiation therapy and clinical
variables on measures of attention among children and young
adults with brain tumors was prospectively examined (Kiehna
et al., 2006). Over the ﬁrst 5 years after treatment, patients with
Cp demonstrated increased inattentiveness and profound inat-
tentiveness was accompanied by markedly slower reaction time.
Overall, newer focal beam radiation techniques demonstrated
improved outcomes in terms of functional performance in up
to 85% of patients (Merchant et al., 2002; Kiehna and Merchant,
2010).
Despite over a quarter of century of literature documenting
the neurocognitive challenges encountered by individuals treated
for Cp, intervention efforts have lagged. Recent case studies have
examined the efﬁcacy of cognitive rehabilitation for dysexecu-
tive problems and behavioral lability (Metzler-Baddeley and Jones,
2010; Hammond and Hall, 2011). In a case report of a 2-month
intervention using a combination of goal management therapy
and naturally occurring distractions within the patients’ work
environment, signiﬁcant improvements in cognitive tests requir-
ing organized behavior were reported. Social, emotional, and/or
behavior problems, most notably aggression, have been reported
(Anderson et al., 1997;Riva et al., 1998; Poretti et al., 2004).Despite
their occurrence, the assumption of the biological underpinning
of the behavioral disturbance appears to have limited attempts to
effectively manage it with intervention. Behavioral treatment was
used for severe aggressive behaviors demonstrated by a 6-year-old
post-Cp resection (Hammond and Hall, 2011); the intervention
included functional behavioral analysis followed by differential
reinforcement of alternative behaviors and extinction with the
goal of decreasing the frequency of aggressive behavior. Aggressive
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behavior subsequently decreased to below 88% of baseline levels
and adaptive behaviors were found to increase signiﬁcantly. These
results suggest that the patient’s aggression was maintained by
inadvertent social reinforcement. Taken together, these case stud-
ies suggest that cognitive rehabilitation approaches such as goal
management therapy and functional behavioral analysis may be
useful in supporting survivors of Cp adept to and compensate for
cognitive and psychosocial challenges.
In light of the cognitive, behavioral, and emotional sequelae
associated with treatment for Cp, monitoring and support is war-
ranted. Ongoing counseling, educational, and advocacy for this
unique group of brain tumor survivors will be key to optimizing
their potential.
GENERAL FOLLOW-UP MANAGEMENT OF CHILDREN WITH
CRANIOPHARYNGIOMA
Follow-up surveillance of the residual tumor or assessment for
recurrence is addressed by the neurosurgery and oncology teams
(see other reviews in this issue). Endocrine follow-up and sur-
veillance should be conducted at least annually in those with no
pituitary abnormalities as these may evolve over time. During
periods of active treatment, or for those with residual pituitary
deﬁcits follow-up should occur more frequently, usually every 3–
6months, to reassess hormone replacement status.When required,
replacement with GH appears to be safe and has not been associ-
ated with an increased risk of tumor recurrence in children and
adults with Cp (Clayton et al., 1988; Price et al., 1998; Karavitaki
et al., 2006). However since there are potential concerns regarding
GH mitogenic activity (Taguchi et al., 2010), ongoing surveil-
lance is advised. For those patients with hypothalamic symptoms
related to Cp management is more of a challenge. Obesity devel-
ops rapidly and early after treatment and appears to be resilient
to traditional weight management methods. Visual deﬁcits and
increased fatigue add further obstacles for those attempting to
increase physical activity. Cognitive and psychological challenges
can further impact daily functioning at home and school. Amulti-
disciplinary approach is essential to address these issues for the
patient and their family.
In 2005,we established an interdisciplinary, comprehensive care
clinic at theHospital for SickChildren inToronto (Rakhshani et al.,
2010). The clinic provided family-centered treatment with med-
ical, behavioral, dietary, and exercise support. Patients attended as
frequently as once per month to routine visits every 6months and
at other times telephone or e-mail communication was available.
Treatment was patient speciﬁc and included group sessions as well
as individual therapy. In certain situations, pharmacologic agents
or speciﬁc diets have been prescribed.
The rate of increase in percent BMI slowed in patients attending
the clinic compared to their prior BMI change while in standard
care. The majority of patients entering the clinic shortly after
diagnosis exhibited stable weight as opposed to the early rapid
weight gain seen in historical controls. There were also signiﬁ-
cant increases in the children’s reported quality of life, physical
functioning, and school functioning after 1 year in the program
with a trend toward less time spent in sedentary activity. Parents
reported improvement in coordination of health care and under-
standing of their child’s disease. These results demonstrate the
beneﬁt of coordinated health care in improving the physical and
psychological well-being of patients and their families.
As discussed earlier, additional therapies to target HO have
been studied. Their mechanisms of action include increasing sym-
pathetic tone (Mason et al., 2002; Ismail et al., 2006; Danielsson
et al., 2007; Schultes et al., 2009), reducing insulin secretion, and
improving sensitivity (Lustig et al., 1999, 2003a; Inge et al., 2007;
Hamilton et al., 2011). Patients have experienced a decrease in
weight gain or weight stabilization but without dramatic weight
reduction. The effect of GH on weight gain has also been sought;
however it was noted to have only a slight beneﬁcial effect on
BMI gain (Geffner et al., 2004). Similar to other populations with
severe obesity, there is growing interest in bariatric surgery as a
mode of therapy in HO. There is only sparse information about
this treatment in Cp individuals with three case reports pub-
lished on four patients (three adolescent, one adult) undergoing
intestinal bypass surgery and one case series of four individu-
als (two adolescent, two young adult) receiving a laparoscopic
adjustable gastric band (LAGB; Inge et al., 2007;Muller et al., 2007;
Rottembourg et al., 2009; Schultes et al., 2009). Gastric bypass
surgery induced signiﬁcant and sustained weight loss, reduction
in feelings of hunger and remarkable improvement in comorbidi-
ties (Inge et al., 2007; Rottembourg et al., 2009; Schultes et al.,
2009). LAGB was reported to induce a continuous decrease in
BMI in four patients with major improvements in eating behav-
ior noted and improved ability to focus on non-food matters
(Muller et al., 2007). In recent years three additional adolescents
followed in our comprehensive care clinic underwent LAGB pro-
cedures with good results in terms of weight stabilization in one
and weight reduction in two (unpublished data). One patient
lost 51% of her excess body weight and was able to sustain a
reduced weight with 2 years follow-up. A major caution, however,
is that bariatric surgery of any kind is a relatively new treat-
ment for adolescents and extensive pre-surgical assessment and
close medical and psychological short and long term follow-up is
needed to ensure that no untoward negative consequences arise.As
such, these procedures should only be performed in experienced
centers and with full support of an interdisciplinary team and
careful assessment and follow-up of biomedical and psychosocial
outcomes.
SURVIVAL AND LATE MORTALITY
Despite a relatively high rate of tumor regrowth, survival in chil-
dren treated for Cp is generally good. However, disease related
mortality can still occur many years after treatment. Data regard-
ing survival includes primarily surgically treated patients. The
reported post-surgical 5-year overall survival is 88–94% (De Vile
et al., 1996; Muller et al., 2001, 2006a; Van Effenterre and Boch,
2002), and the reported 10-year overall survival is 70–92% (Hoff-
man et al., 1992;Van Effenterre and Boch, 2002; Poretti et al., 2004;
Elliott andWisoff, 2010;Visser et al., 2010) with a 20-year survival
of 76%. Survival rates of patients treated with combined surgery
and radiation are comparable (Stripp et al., 2004; Merchant et al.,
2006; Lin et al., 2008; Crom et al., 2010). Causes of late mortality
include causes directly related to the tumor or treatment such as
progressive disease with multiple recurrences, hormonal deﬁcien-
cies, chronic hypothalamic insufﬁciency, cerebrovascular disease,
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and seizure related (De Vile et al., 1996; Poretti et al., 2004; Elliott
and Wisoff, 2010; Visser et al., 2010; Steno et al., 2011). Other
causes have been described including head trauma, drug abuse, or
liver failure (Poretti et al., 2004; Caldarelli et al., 2005; Visser et al.,
2010).
In a study that compared the primary treatment modality used
in a group of survivors to that used in patients who died, no
particular pattern emerged. This might be related the small num-
bers of patients in each survival–treatment group (Visser et al.,
2010), however, this ﬁnding is further supported by similar 5 year
survival rates in patients who did or did not receive radiother-
apy (Muller et al., 2006a). Based on other reports, risk factors for
decreased survival were recurrent resections of tumor regrowth
(Elliott and Wisoff, 2010), and tumor location, with improved
survival for tumors that grow beneath the sellar diaphragm (Steno
et al., 2011).
CONCLUSION
Although treatment for pediatric Cp tumors remains challenging,
changes in management show potential for improved long term
outcomes. Common long term complications include endocrine,
neurologic, psychosocial, and neurocognitive and metabolic mor-
bidities. However, the most signiﬁcant adverse effect on quality of
life are those related to hypothalamic dysfunction and in particu-
lar, post-surgical weight gain and increased fatigue with daytime
somnolence. In recent years there is a trend toward individualiz-
ing treatment based on patient and tumor characteristics as well
as managing Cp more as a chronic disease with less aggressive
surgical treatment and/or adjuvant radiation or chemotherapy.
A coordinated interdisciplinary approach to management, begin-
ning at the time of diagnosis, is very important to identify risk
factors for adverse outcomes, and provide support and education
for these patients and their families.
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